RestructuringJun 24, 2026, 09:06 AM
ADC Therapeutics Cuts 17% Workforce for $10M Annual Savings
AI Summary
ADC Therapeutics SA announced a strategic reorganization involving a global workforce reduction of approximately 17%. This move is expected to generate annualized cost savings of about $10 million, with one-time pre-tax charges of $3 million primarily in Q2 2026. The restructuring aims to enhance financial flexibility and focus resources on key initiatives for its ZYNLONTA franchise, including upcoming regulatory milestones like an FDA meeting in August and an sBLA submission in Q4 2026.
Key Highlights
- ADC Therapeutics plans to reduce its global workforce by approximately 17%.
- The reduction is expected to generate annualized estimated cost savings of approximately $10 million.
- The company estimates one-time pre-tax charges of approximately $3 million for severance and related costs.
- The majority of these charges will be recognized in the second quarter of 2026.
- The company expects a cash runway into at least 2028.
- A pre-sBLA meeting with the FDA is scheduled for August 2026 regarding ZYNLONTA.
- An sBLA submission related to LOTIS-5 is anticipated in Q4 2026.
- Full LOTIS-7 trial data is expected by the end of 2026.
Price Impact
More from ADCT